Memorial Sloan Kettering

Site:	Memorial Sloan Kettering	Go to their website
Address:	1275 York Ave
City:	New York
State:	NY
Zip:	10065
Country:	USA

44 trials at this site

Phase	Trial	Trial Status	Site Status [desc]	Drug	NCT#
2	Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)	Withdrawn	Not yet activated	Ripretinib plus Binimetinib	NCT05080621
1/2	BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Completed	Closed	Imatinib + BGJ398	NCT02257541
1b/2	MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	Imatinib + MEK162	NCT01991379
1/2	A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Active, not recruiting	Closed	THE-630	NCT05160168
3	SU011248 in Treating Patients With Malignant Gastrointestinal Stromal Tumor	Completed	Closed	Sunitinib	NCT00085618
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
2	Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate	Ongoing, but not recruiting	Closed	Sorafenib (Nexavar, BAY 43-9006)	NCT00265798
2	An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment	Completed	Closed	BIIB021 (CNF2024)	NCT00618319
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
2	Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma	Ongoing, but not recruiting	Closed	Cixutumumab + Temsirolimus	NCT01016015
2	Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma	Completed	Closed	Nivolumab + Ipilimumab	NCT02500797
2	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	Closed	Entrectinib	NCT02568267
1	Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery	Completed	Closed	Doxorubicin + Flavopiridol	NCT00098579
1	A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors	Ongoing, but not recruiting	Closed	R1507	NCT00560144
1	Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor	Completed	Closed	KW2450	NCT00921336
1	GDC-0449 and RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma	Completed	Closed	GDC-0449 + RO4929097	NCT01154452
1	Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot be Removed by Surgery or Are Metastatic	Completed	Closed	Dasatinib + Ipilimumab	NCT01643278
1	Safety Study of PLX108-01 in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 (PLX108-01)	NCT01004861
1	Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BKM120 + MEK162	NCT01363232

Memorial Sloan Kettering

44 trials at this site

Page 1 of 3 | Next | Last